The University of Chicago Header Logo

Connection

Mark Kozloff to Epithelial-Mesenchymal Transition

Back to Details
This is a "connection" page, showing publications Mark Kozloff has written about Epithelial-Mesenchymal Transition.
Mark Kozloff
Connection Strength
0.138
Epithelial-Mesenchymal Transition
  1. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist. 2017 03; 22(3):264-271.
    View in: PubMed
    Score: 0.138
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.